Shanghai Women's Health Study | Shanghai Men's Health Study | Pooled multivariable model (men and women) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | N | |||||||||||||
Cases | Non-cases | Age-aHR | 95% CI | M-aHR | 95% CI | Cases | Non-cases | Age-HR | 95% CI | M-aHR | 95% CI | M-aHR | 95% CI | |
Baseline cholelithiasis and/or cholecystectomy (yes/no) | 37/123 | 8293/64 756 | 1.74 | 1.20 to 2.53 | 1.55 | 1.06 to 2.26 | 38/214 | 4747/56 338 | 1.74 | 1.22 to 2.46 | 1.46 | 1.02 to 2.07 | 1.50 | 1.16 to 1.94 |
Baseline cholelithiasis (yes/no) | 35/125 | 8126/64 923 | 1.66 | 1.14 to 2.43 | 1.47 | 1.00 to 2.17 | 38/214 | 4576/56 509 | 1.80 | 1.27 to 2.56 | 1.51 | 1.06 to 2.15 | 1.49 | 1.15 to 1.94 |
Repeated measures of cholelithiasis (yes/no) | T1: 25/70 T2: 18/47 | T1: 8136/64 978 T2: 9355/56 732 | 1.98 | 1.39 to 2.82 | 1.80 | 1.25 to 2.57 | T1: 21/100 T2: 21/110 | T1: 4593/56 623 T2: 4114/45 422 | 1.94 | 1.39 to 2.72 | 1.69 | 1.20 to 2.37 | 1.74 | 1.36 to 2.22 |
Concordant reported cholelithiasis (yes/no)* | 15/62 | 6032/56 789 | 1.68 | 0.95 to 2.97 | 1.49 | 0.83 to 2.66 | 24/195 | 3220/53 777 | 1.60 | 1.04 to 2.46 | 1.34 | 0.87 to 2.06 | 1.39 | 0.98 to 1.96 |
Baseline cholecystectomy (yes/no) | 15/145 | 3136/69 913 | 1.63 | 0.96 to 2.79 | 1.56 | 0.91 to 2.67 | 11/241 | 1673/59 412 | 1.31 | 0.71 to 2.40 | 1.18 | 0.64 to 2.17 | 1.38 | 0.92 to 2.07 |
Multivariable model adjusted for age, education, income, smoking status, alcohol consumption, menopausal status (for women only), family history of liver cancer, BMI, physical activity, total energy intake and history of diabetes and hepatitis/chronic liver disease.
*Excludes 10 311 women and 4121 men who did not consistently report a history of cholelithiasis at baseline and follow-up (5217 women and 2603 men) or were missing follow-up data (5094 women and 1518 men).
Age-aHR, age-adjusted hazard ratio; BMI, body mass index; M-aHR, multivariable adjusted hazard ratio; N, number; T1, baseline to follow-up interview; T2, follow-up interview to the end of follow-up.